News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Subscribe To Our Newsletter & Stay Updated
